Bayer’s Legal Crossroads: A $5 Billion Cash Drain Meets a Supreme Court Pivot Point

Bayer's April 27 Supreme Court hearing on Roundup preemption could reshape its legal landscape, as €11.8B in provisions and a $7.25B settlement loom.

The calendar at Bayer is unusually crowded. On April 27, the US Supreme Court will hear oral arguments in a case that could reshape the company’s legal landscape, while that same day marks the ex-dividend date for a token payout of €0.11 per share. The convergence is a stark reminder of how litigation risk now dominates nearly every aspect of the German conglomerate’s financial life.

At the heart of the Supreme Court hearing is a question with multibillion-dollar consequences: Does federal law under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) preempt state-level failure-to-warn claims against glyphosate-based products like Roundup? Bayer has long argued that it does. If the justices agree, roughly 65,000 pending lawsuits would lose their legal footing. The Trump administration has filed a brief supporting Bayer’s position, while attorneys general from 18 states — including Texas and Florida — have submitted arguments defending state sovereignty.

A ruling is expected by June 2026. In the meantime, the financial toll continues to mount. Bayer carries provisions of €11.8 billion for litigation, the vast majority tied to Roundup. The company anticipates cash outflows of roughly €5 billion in 2026 alone — enough to push free cash flow deep into negative territory.

A Settlement in Motion, But Not Yet Final

Parallel to the Supreme Court proceedings, Bayer is pushing forward with a $7.25 billion settlement package. It received preliminary approval in Missouri, with a June 4 deadline for claimants to opt out. CEO Bill Anderson described the situation as “dynamic, with important milestones and decisions in the coming weeks,” stopping short of declaring the matter resolved.

The legal drag was laid bare in the full-year 2025 results. Litigation expenses of €6.2 billion pushed the group to a net loss of €3.6 billion, even as revenue reached €45.6 billion and adjusted earnings per share came in at €4.91 — within the company’s own guidance.

Pipeline Progress Offers a Counterpoint

Not everything is grim. Anderson used the annual general meeting, held three days before the Supreme Court date, to highlight operational bright spots. The oncology drug Nubeqa and the kidney treatment Kerendia together grew 68% in 2025. For 2026, Bayer forecasts currency-adjusted revenue between €45 billion and €47 billion, with operating EBITDA in a range of €9.6 billion to €10.1 billion.

“We have made significant progress, but the work is not yet complete,” Anderson told shareholders. He described 2026 as “a fundamentally solid year that has started well.”

Boardroom Changes and a New Finance Chief

The supervisory board is getting two new capital-side representatives. Marcel Smits, former CFO and strategy chief at Cargill, brings expertise in global supply chains. Alfred Stern, currently CEO of OMV, adds experience in corporate governance and sustainability. They replace Paul Achleitner and Colleen Goggins.

On the management board, Dr. Judith Hartmann will take over as CFO on June 1, succeeding Wolfgang Nickl, who departs at the end of May. Anderson’s contract was extended through March 2029, while pharmaceuticals chief Stefan Oelrich is now tied to the company until October 2029.

Stock Under Pressure, Catalysts Ahead

Bayer shares closed Friday at €38.50, down nearly 4% on the day and roughly 22% below the February high of €49.17. The stock now trades about 5% below its 50-day moving average and has fallen more than 20% from its 52-week peak.

First-quarter results are due on May 12. They will offer the first concrete test of whether Anderson’s cautious optimism has operational substance — and whether investors can look beyond the legal cloud that has hung over the stock since the Monsanto acquisition.